Watermark

Advancing Global Health

Our Unique Approach

Our expansive internal resources and capabilities enhance our control over quality, speed, cost, and risk — key factors in delivering innovative, safe, and accessible therapies to patients worldwide.

Reaching every patient who needs our medicines, regardless of where they live, is central to our work.

Our business is structured to broaden global access to innovative cancer therapies through the following strategic advantages:

  • A fully integrated in-house model that connects early patient perspectives, research, translational science, and clinical execution, so we can learn fast, act with rigor, and scale what works.
  • An agile manufacturing network that can act quickly when breakthroughs emerge, maintain tight quality control for complex medicines, and respond with the speed cancer patients need from clinical development through commercialization.
  • A global footprint across six continents that facilitates collaboration with health systems around the world and supports a community-first approach shaped by the knowledge that the barriers patients face are rarely the same from one place to the next.
  • Strategic partnerships that help us overcome barriers and reach patients in underserved communities.

Upholding our value of Patients First, our Global Patient Safety team ensures the safety and effectiveness of our medicines from their first use in clinical trials to post-commercialization.

For more information about our Science, please visit Medicines, Research & Development, and Pipeline.

We think about access in the following ways:

Global access through research & development

Global access through manufacturing

Global access through local pathways

Global access through community collaboration

Global access through philanthropy

As part of this commitment, we provide investigational medicines to patients with no other options. To learn more, visit Expanded Access Programs. We also provide personalized assistance to patients prescribed our medications through our Patient Support Program.

Learn More About Our Commitment To Access

Patient Engagement & Advocacy

We seek to ensure that our approach to drug development and commercialization accurately reflects patients’ true lived experiences and expectations—a central component of providing patients with meaningful treatment. To accomplish this, we partner with patient communities, advocate for patient priorities, and turn awareness into action through strategic campaigns, such as talk about it™, which highlights the intersection of cancer and mental health.

Throughout clinical development, we aim to ensure our therapies meet their needs and that those who need these medicines can access them.

Our strategies for global patient advocacy vary based on local healthcare systems, but in all regions we seek to identify and address barriers to treatment access. To date, we’ve built partnerships with 75+ advocacy organizations worldwide focused on education, earlier diagnosis, clinical trial awareness, and reducing barriers to care.

A crucial component of our success lies in ensuring the independence of patient organizations. These commitments are detailed in our Global Policy Position on Partnering with Patient Organizations.

To learn more about how we strive to meet patients where they are — across geographies, healthcare systems, and moments in the treatment journey, read our commitment to Global Access Through Local Pathways.

You can also read about how we advance global health and other Responsible Business & Sustainability initiatives.